Cerus Corporation develops and commercializes the INTERCEPT Blood System to enhance blood safety. The company offers systems for platelets, plasma, and red blood cells to reduce blood-borne pathogens. Its products are sold through a direct sales force and distributors globally. Cerus also produces pathogen-reduced cryoprecipitated fibrinogen complex and plasma. The company was incorporated in 1991 and is headquartered in California.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 31.0 |
| ROIC | 8.1% |
| Net Debt/EBITDA | 100.0 |